

3M Science.
Applied to Life.™

**3M™ Tegaderm™ CHG
I.V. Securement Dressing**

NICE Medical Technology Guidance 2019.

The case for adopting Tegaderm CHG securement dressing is supported by the evidence.

3M Tegaderm CHG securement dressing should be considered for use in critically ill adults who need a central venous (CVC) or arterial catheter in intensive care or high dependency units.

Adult critical care patients annually
113,920–291,836*



95% of episodes
require a CVC/CAC

Estimated cost saving from using a Tegaderm CHG dressing instead of a standard transparent semipermeable dressing is




£93 per patient

*HES Data 2017–2018

£4.2m – £10.8m annual savings

The annual saving for critical care patients from implementing Tegaderm CHG securement dressing for England will be between £4.2M (intensive care episodes > 48 hours) and £10.8M (for all intensive care episodes) based on a catheter-related bloodstream infection (CRBSI) incidence of 1.48/1000 catheter days.

The NICE committee concluded that Tegaderm CHG securement dressing continues to be cost saving until CRBSI rate reaches 0.18/1000 catheter days at which point it becomes cost neutral.



Source: Medical technologies guidance [MTG25] Published date: September 2019. The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites www.nice.org.uk/guidance/mtg25

GF522. OMG65192.
3M and Tegaderm are trademarks of 3M Company. © 3M 2020. All rights reserved.